Compare KWR & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | AVDL |
|---|---|---|
| Founded | 1918 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 1985 | 1996 |
| Metric | KWR | AVDL |
|---|---|---|
| Price | $155.39 | $21.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $149.25 | $18.38 |
| AVG Volume (30 Days) | 135.5K | ★ 1.5M |
| Earning Date | 02-23-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,864,242,000.00 | $248,517,000.00 |
| Revenue This Year | $3.44 | $65.47 |
| Revenue Next Year | $4.15 | $30.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.08 | ★ 79.88 |
| 52 Week Low | $95.91 | $6.38 |
| 52 Week High | $154.08 | $23.57 |
| Indicator | KWR | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 72.02 | 58.63 |
| Support Level | $136.34 | $21.45 |
| Resistance Level | $145.30 | $21.56 |
| Average True Range (ATR) | 4.27 | 0.09 |
| MACD | 1.26 | -0.05 |
| Stochastic Oscillator | 99.76 | 49.09 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.